What Is Cagrilintide? The Amylin Analog Explained

The short answer

Cagrilintide is a long-acting amylin analog — a synthetic peptide engineered to mimic and extend the action of amylin, one of the body's natural appetite-regulating hormones. It's being developed by Novo Nordisk, primarily for obesity, and is most prominent as one half of the CagriSema combination (cagrilintide + semaglutide).

As of 2026, cagrilintide is not FDA-approved. It's in late-stage clinical development — the Phase 3 REDEFINE program is ongoing.

What is amylin, the hormone cagrilintide mimics?

To understand cagrilintide, you need to understand amylin. Amylin is a 37-amino-acid peptide hormone produced by the pancreas. Critically, it's co-secreted with insulin — every time beta cells release insulin in response to food, they release amylin alongside it.

Amylin's jobs include:

• Promoting satiety — signaling fullness to the brain through receptors in the hindbrain
• Slowing gastric emptying — keeping food in the stomach longer, extending the sense of fullness
• Suppressing inappropriate glucagon — preventing the liver from releasing excess glucose after meals

This biology overlaps with GLP-1 in its effects (both promote satiety, both slow gastric emptying) but works through different receptors and different neural circuits. Amylin acts on calcitonin-receptor complexes; GLP-1 acts on GLP-1 receptors. That distinction is the entire reason cagrilintide is interesting — it's a complementary mechanism, not a redundant one.

Why amylin needed engineering

Native amylin has properties that make it difficult to use as a drug. It's chemically unstable and prone to forming amyloid aggregates — sticky clumps that limit shelf life and usability. It also has a very short half-life.

The first solution was pramlintide (brand name Symlin), an amylin analog FDA-approved back in 2005. Pramlintide solved the aggregation problem with amino-acid substitutions, but it still has a short half-life — it requires injection three times a day, alongside mealtime insulin. That dosing burden limited its adoption.

Cagrilintide is the modern answer. It's engineered for once-weekly dosing — the same convenient schedule as semaglutide and tirzepatide. That's the key advance: amylin-pathway benefits without the three-times-daily injection burden of pramlintide.

How cagrilintide works

Cagrilintide activates amylin receptors (calcitonin-receptor complexes paired with receptor-activity-modifying proteins). The downstream effects mirror natural amylin: enhanced satiety, slowed gastric emptying, and reduced food intake.

In Phase 2 testing as a standalone treatment, once-weekly cagrilintide produced clinically meaningful weight loss in adults with obesity — in the range that approached early-generation GLP-1 monotherapy at the time. As a standalone, it works.

But the standalone weight-loss numbers aren't the main story. Tirzepatide and semaglutide already produce substantial weight loss on their own. The strategic value of cagrilintide is what happens when you combine it with a GLP-1.

CagriSema: the combination that matters

CagriSema is the fixed combination of cagrilintide plus semaglutide — amylin-pathway agonism plus GLP-1-pathway agonism in one product.

The logic is mechanistic complementarity. GLP-1 and amylin both suppress appetite, but through different receptors and different brain circuits. Combining them should produce additive appetite suppression — more than either alone — without simply doubling the side effects of a single pathway.

Phase 2 data supported this: CagriSema produced greater weight loss than either cagrilintide or semaglutide alone. The Phase 3 REDEFINE program is testing the combination at scale across obesity and type-2-diabetes populations, with a cardiovascular outcomes trial included.

If approved, CagriSema would be one of the first fixed-combination obesity medications built from two distinct mechanism arms. For a deeper look, see our dedicated article on the CagriSema Phase 3 program.

How cagrilintide differs from GLP-1 drugs

People often encounter cagrilintide alongside semaglutide and tirzepatide and assume it's "another GLP-1." It isn't.

They're complementary, not interchangeable. That complementarity is the whole point of combining them.

Where cagrilintide sits in the 2026 pipeline

Cagrilintide is one of several next-wave obesity-pharmacology programs. Its position:

• Standalone cagrilintide — possible future approval, but the standalone weight-loss magnitude is less than current GLP-1 monotherapy, so the standalone path is less commercially compelling.
• CagriSema — the main program. Phase 3 readouts staggered through 2025-2026; potential approval 2026-2027.

The CagriSema program has had some complexity — initial Phase 3 readouts showed weight-loss magnitudes that were real but somewhat below the most optimistic analyst expectations. That's not unusual for combination products and doesn't preclude approval, but it has tempered some of the early enthusiasm.

For users tracking the obesity-medicine pipeline, cagrilintide is significant as the proof-of-concept for the amylin-combination strategy — an alternative to the receptor-stacking approach embodied by tirzepatide and retatrutide.

Can you get cagrilintide now?

Not through FDA-approved channels — it isn't approved. Cagrilintide appears in grey-market research-peptide channels, where it carries the standard concerns of that ecosystem: unverified identity and purity, no clinical oversight, and uncharacterized real-world dosing.

The amylin-pathway benefit that cagrilintide represents is partially accessible today through pramlintide, the FDA-approved amylin analog — though pramlintide's three-times-daily dosing is a real practical limitation. Some clinicians use pramlintide off-label alongside GLP-1 therapy as an approximation of the CagriSema concept.

For most people, the practical answer is: cagrilintide is a compound to watch, not one to use, until the CagriSema Phase 3 program completes and a regulatory decision is made.